Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
4.870
+0.220 (4.73%)
Mar 6, 2026, 2:46 PM EST - Market open

Aldeyra Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Selling, General & Admin
9.611.8913.3415.3711.28
Upgrade
Research & Development
25.6648.2229.4647.3144.94
Upgrade
Operating Expenses
35.2760.1242.7962.6856.22
Upgrade
Operating Income
-35.27-60.12-42.79-62.68-56.22
Upgrade
Interest Expense
-1.91-1.93-2.07-1.69-1.74
Upgrade
Interest & Investment Income
3.326.197.322.350.19
Upgrade
EBT Excluding Unusual Items
-33.85-55.85-37.54-62.02-57.78
Upgrade
Pretax Income
-33.85-55.85-37.54-62.02-57.78
Upgrade
Net Income
-33.85-55.85-37.54-62.02-57.78
Upgrade
Net Income to Common
-33.85-55.85-37.54-62.02-57.78
Upgrade
Shares Outstanding (Basic)
6059595854
Upgrade
Shares Outstanding (Diluted)
6059595854
Upgrade
Shares Change (YoY)
0.96%0.92%0.92%8.08%59.11%
Upgrade
EPS (Basic)
-0.56-0.94-0.64-1.06-1.07
Upgrade
EPS (Diluted)
-0.56-0.94-0.64-1.06-1.07
Upgrade
Free Cash Flow
-33.35-43.21-30.33-56.65-42.56
Upgrade
Free Cash Flow Per Share
-0.56-0.73-0.51-0.97-0.79
Upgrade
EBITDA
-35.01-59.87-42.53-62.42-55.96
Upgrade
D&A For EBITDA
0.250.250.260.260.26
Upgrade
EBIT
-35.27-60.12-42.79-62.68-56.22
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.